Share:
062021LSReportherosmall 062021LSReportheroLarge

Insights

Life Sciences on the Rise - North American Report

Download Report

Innovative technologies and aging demographics are driving a wave of demand for R&D space, diagnostic centers and healthcare facilities.

The global life sciences industry has been on the rise, growing more rapidly than ever over the past decade—well before the pandemic struck. In fact, its trajectory only accelerated throughout 2020 and into early 2021—with demand for its products surging and access to capital continuing to greatly expand in both periods. A record $70 billion of private and public capital (mostly venture capital and initial  public offerings) poured into life sciences-related companies in North America in 2020, a 93% increase from the previous record of $36 billion received in 2018. And if investment continues at the pace we’ve seen in the first quarter of 2021 (already totaling $32.9 billion), we could see somewhere in the area of $90 billion raised this year alone. 

With COVID-19 challenging the sector last year like never before, the industry has clearly proven itself, sparking a light that illuminated a better way to work, collaborate and innovate toward the hope of a vaccinated future. The speed at which COVID-19 vaccines have been developed and rolled out is a huge achievement for the pharmaceutical and biotechnology industries and is also a testament to the power of global collaboration. Now that we know what’s achievable in a relatively short amount of time, many will ponder what’s next for the life sciences industry. What else is it capable of doing?   

Key takeaways include:

  • The global life sciences industry has been on the rise, growing more rapidly than ever over the past decade; its trajectory only strengthened throughout 2020 and going into 2021. 
  • COVID-19 has further cemented the strength of the life sciences industry with mRNA technology opening the door to new possibilities. 
  • Life sciences is a good alternative asset category for investors since sector is appearing to be recession-proof. 

Read more about the Global Life Sciences Industry in 2021.

Does your building qualify for a life science conversion? Explore our checklist.

 

View Markets

Austin-thumbnail
Austin

 

View in Report

Read the Report - Boston
Boston

 

View in Report

Denver-thumbnail
Denver

 

View in Report

LA-thumbnail
Los Angeles

 

View in Report

Read the Report - Montreal
Montreal

 

View in Report

Read the Report - New Jersey
New Jersey

 

View in Report

Read the Report - NYC
New York City

 

View in Report

Read the Report - Philly
Philadelphia

 

View in Report

Read the Report - Research Triangle
Raleigh / Durham

 

View in Report

SLC-thumbnail
Salt Lake City

 

View in Report

Reand the Report - San Diego
San Diego

 

View in Report

Read the Report - San Francisco
San Francisco Bay Area

 

View in Report

Read the Report Seattle
Seattle

 

View in Report

Read the Report - Toronto
Toronto

 

View in Report

Vancouver-thumbnail
Vancouver

 

View in Report

Authors

Kenneth McCarthy New York Research
Kenneth McCarthy

Economist, Global Research
New York, United States


+1 (212) 698-2502 x332502

Download VCard

Sandy Romero New York Research
Sandy Romero

Senior Analyst Research
New York, United States


Download VCard

Brendan Carroll Boston
Brendan Carroll

Research Director
Boston, United States


+1 (617) 2794565

Download VCard

Related Insights

LifeSciences-Checklist_card
Article • Office

Does your building qualify for a life sciences conversion?

Interest in converting assets for life sciences use is growing amongst building owners. Cushman & Wakefield’s Project & Development Services team developed basic building performance criteria based on the minimum standards that life sciences companies typically require. 
Daniel Hackett • 5/10/2021
Life sciences covid-19 (image)
Research • Lab

Life Sciences: COVID-19 Report

Featured local market snapshots give an overview into the life sciences sector and the impact of the pandemic, establishing a baseline for analyzing potential impact in the months to come.
Kenneth McCarthy • 6/26/2020
New Normal (image)
Research • Healthcare

Is COVID-19 Healthcare’s Kryptonite?

Will the duration of COVID-19 highlight the vulnerability of the healthcare sector and lead to a reassessment of its much discussed “recession-resistance”? Or, will this pandemic reinforce and underscore healthcare’s sustainable, steady strength? Read Cushman & Wakefield's latest report that addresses these questions.
Lorie Damon • 12/9/2020

Ready to talk?

We look forward to connecting with you.